Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Socioeconomic Status as a Determinant of Health Status Treatment Response in COPD Trials.

Jones PW, Gelhorn H, Wilson H, Benson VS, Karlsson N, Menjoge S, Müllerova H, Rennard SI, Tal-Singer R, Merrill D, Tabberer M.

Chronic Obstr Pulm Dis. 2017 Apr 1;4(2):150-158. doi: 10.15326/jcopdf.4.2.2017.0132.

2.

St George's Respiratory Questionnaire Score Predicts Outcomes in Patients with COPD: Analysis of Individual Patient Data in the COPD Biomarkers Qualification Consortium Database.

Müllerova H, Gelhorn H, Wilson H, Benson VS, Karlsson N, Menjoge S, Rennard SI, Tabberer M, Tal-Singer R, Merrill D, Jones PW.

Chronic Obstr Pulm Dis. 2017 Mar 28;4(2):141-149. doi: 10.15326/jcopdf.4.2.2017.0131.

3.

Baseline Severity as Predictor of Change in St George's Respiratory Questionnaire Scores in Trials of Long-acting Bronchodilators with COPD Patients.

Jones PW, Gelhorn H, Karlsson N, Menjoge S, Müllerova H, Rennard SI, Tal-Singer R, Wilson H, Merrill D, Tabberer M.

Chronic Obstr Pulm Dis. 2017 Mar 21;4(2):132-140. doi: 10.15326/jcopdf.4.2.2017.0129.

4.

Responder Analyses for Treatment Effects in COPD Using the St George's Respiratory Questionnaire.

Jones PW, Gelhorn H, Wilson H, Karlsson N, Menjoge S, Müllerova H, Rennard SI, Tal-Singer R, Merrill D, Tabberer M.

Chronic Obstr Pulm Dis. 2017 Mar 2;4(2):124-131. doi: 10.15326/jcopdf.4.2.2017.0130.

5.

The COPD Biomarkers Qualification Consortium Database: Baseline Characteristics of the St George's Respiratory Questionnaire Dataset.

Tabberer M, Benson VS, Gelhorn H, Wilson H, Karlsson N, Müllerova H, Menjoge S, Rennard SI, Tal-Singer R, Merrill D, Jones PW.

Chronic Obstr Pulm Dis. 2017 Mar 13;4(2):112-123. doi: 10.15326/jcopdf.4.2.2017.0128.

6.

Assessing consistent treatment effect in a multi-regional clinical trial: a systematic review.

Chen J, Quan H, Binkowitz B, Ouyang SP, Tanaka Y, Li G, Menjoge S, Ibia E; Consistency Workstream of the PhRMA MRCT Key Issue Team.

Pharm Stat. 2010 Jul-Sep;9(3):242-53. doi: 10.1002/pst.438. Review.

PMID:
20872623
7.

Patient-level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalisations.

Halpin D, Menjoge S, Viel K.

Prim Care Respir J. 2009 Jun;18(2):106-13. doi: 10.4104/pcrj.2009.00017.

8.

A 4-year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial).

Tashkin D, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M.

Rev Port Pneumol. 2009 Jan-Feb;15(1):137-40. doi: 10.1016/S0873-2159(15)30121-5. English, Portuguese. No abstract available.

9.

Statistical analysis of chronic obstructive pulmonary disease (COPD) exacerbations.

Liu D, Menjoge S.

Eur Respir J. 2008 Nov;32(5):1422-3; author reply 1423. doi: 10.1183/09031936.00124108. No abstract available.

10.

A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators.

N Engl J Med. 2008 Oct 9;359(15):1543-54. doi: 10.1056/NEJMoa0805800. Epub 2008 Oct 5.

11.

Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids.

Hodder R, Kesten S, Menjoge S, Viel K.

Int J Chron Obstruct Pulmon Dis. 2007;2(2):157-67.

12.

Tiotropium in COPD patients not previously receiving maintenance respiratory medications.

Adams SG, Anzueto A, Briggs DD Jr, Menjoge SS, Kesten S.

Respir Med. 2006 Sep;100(9):1495-503. Epub 2006 May 15.

13.

One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium.

Anzueto A, Tashkin D, Menjoge S, Kesten S.

Pulm Pharmacol Ther. 2005;18(2):75-81. Epub 2004 Dec 20.

PMID:
15649848
15.

Tolerance to bronchodilating effects of salmeterol in COPD.

Donohue JF, Menjoge S, Kesten S.

Respir Med. 2003 Sep;97(9):1014-20.

16.

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.

Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr.

Eur Respir J. 2002 Feb;19(2):217-24.

17.

The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group.

Casaburi R, Briggs DD Jr, Donohue JF, Serby CW, Menjoge SS, Witek TJ Jr.

Chest. 2000 Nov;118(5):1294-302.

PMID:
11083677
18.

Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease.

Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, Witek TJ Jr.

Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1136-42.

PMID:
10764302
19.

The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD.

Dorinsky PM, Reisner C, Ferguson GT, Menjoge SS, Serby CW, Witek TJ Jr.

Chest. 1999 Apr;115(4):966-71.

PMID:
10208193
20.

Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD.

Friedman M, Serby CW, Menjoge SS, Wilson JD, Hilleman DE, Witek TJ Jr.

Chest. 1999 Mar;115(3):635-41.

PMID:
10084468
21.

Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995.

Van Andel AE, Reisner C, Menjoge SS, Witek TJ.

Chest. 1999 Mar;115(3):703-7.

PMID:
10084479
22.

A comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma.

Karpel JP, Schacter EN, Fanta C, Levey D, Spiro P, Aldrich T, Menjoge SS, Witek TJ.

Chest. 1996 Sep;110(3):611-6.

PMID:
8797400

Supplemental Content

Loading ...
Support Center